Literature DB >> 2730377

Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?

J C Morris1, M Drazner, K Fulling, E A Grant, J Goldring.   

Abstract

To examine the natural history and pathogenesis of parkinsonism in Alzheimer's disease, 44 subjects with clearly established senile dementia of the Alzheimer type were studied during a 66-month period. Sixteen subjects (36%) developed idiopathic parkinsonism, and 12 subjects (27%) developed drug-induced parkinsonism; the chief clinical features of both types were bradykinesia and rigidity, but not resting tremor. The presence of parkinsonism was associated with global (rather than selective) cognitive impairment, as determined by psychometric testing, and with more rapid progression to advanced stages of dementia. The pathological correlates of clinical parkinsonism were heterogeneous in 10 subjects with Alzheimer's disease who were examined post mortem. Coexistent Parkinson's disease was observed in five cases and nonspecific nigral degenerative lesions were present in another three; however, two cases had neither histological changes nor reduced neuronal densities in the substantia nigra. These two cases suggested that extranigral lesions, possibly involving mesocortical dopaminergic pathways, may contribute to the development of parkinsonism in subjects with Alzheimer's disease.

Entities:  

Mesh:

Year:  1989        PMID: 2730377     DOI: 10.1001/archneur.1989.00520420071025

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  23 in total

1.  Selective loss of nigral neurons in Alzheimer's disease: a morphometric study.

Authors:  T Uchihara; H Kondo; K Kosaka; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 2.  Alzheimer's disease.

Authors:  M Rossor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

3.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

4.  Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit.

Authors:  Steven Theroux; Mandy Pereira; Kimberly S Casten; Rebecca D Burwell; Kam C Yeung; John M Sedivy; Jan Klysik
Journal:  Brain Res Bull       Date:  2006-12-11       Impact factor: 4.077

5.  Pathogenesis of mild parkinsonian signs in aging.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2014-10-28       Impact factor: 4.849

Review 6.  Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases.

Authors:  Jing L Guo; Virginia M Y Lee
Journal:  Nat Med       Date:  2014-02       Impact factor: 53.440

7.  A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.

Authors:  M Yoshita; J Taki; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

8.  A Case of Biopsy-proven Early-onset Alzheimer's Disease with Hemiparkinsonism.

Authors:  Eun Jung Choi; Hyun Bang; Joo Hyuk Im; Sun Joo Chung; Jae-Hong Lee
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

9.  Substantia innominata: MR findings in Parkinson's disease.

Authors:  Hirobumi Oikawa; Makoto Sasaki; Shigeru Ehara; Takashi Abe
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

10.  Gray matter atrophy associated with extrapyramidal signs in the Lewy body variant of Alzheimer's disease.

Authors:  Seong Hye Choi; Mikel Olabarrieta; Oscar L Lopez; Victoria Maruca; Steven T Dekosky; Ronald L Hamilton; James T Becker
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.